Alvotech hands Fuji rights to Japan lines

Alvotech has given Japanese firm Fuji Pharma exclusive commercial rights to its biosimilars portfolio in Japan. Under the deal, Alvotech will be responsible for developing and supplying biosimilars within its pipeline that currently includes rivals to AbbVie’s Humira (adalimumab) and Janssen’s Stelara (ustekinumab), the latter using perfusion fermentation technology.